Overview
To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year
Eligibility
Main Inclusion Criteria:
- Postmenopausal women
- Patients diagnosed with postmenopausal osteoporosis and administered denosumab for 1 year
Main Exclusion Criteria:
- Any contraindication to risedronate
- Those evaluated as inappropriate at the discretion of the investigator